Triple-Drug cocktail aims to make inoperable liver cancer removable
NCT ID NCT06796803
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests whether combining an immunotherapy drug (camrelizumab), a targeted therapy (rivoceranib), and liver-directed chemotherapy (HAIC) can shrink intermediate-to-advanced liver tumors enough to allow surgical removal. About 400 adults with potentially resectable hepatocellular carcinoma will be randomly assigned to receive the triple combination or just the two systemic drugs. The main goals are to see how many patients achieve a complete tumor removal with clear margins and how long they live without the cancer coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC)
- What this could lead to
- If successful, this approach could shrink advanced liver tumors enough to allow surgical removal, potentially curing more patients who otherwise have limited options.
- What could go wrong
- This is a mid-stage trial, so the combination may not work better than standard therapy and could cause serious side effects from the immune system or chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POTENTIALLY RESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150000, China
Contact
-
Zhongshan Hospital
RECRUITINGShanghai, Shanghai Municipality, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.